Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002582638 | SCV002933231 | uncertain significance | not provided | 2022-08-09 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 1149 of the LAMA1 protein (p.Pro1149Leu). This variant is present in population databases (rs764502367, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with LAMA1-related conditions. |
Ambry Genetics | RCV004064375 | SCV004894195 | uncertain significance | Inborn genetic diseases | 2023-10-17 | criteria provided, single submitter | clinical testing | The c.3446C>T (p.P1149L) alteration is located in exon 24 (coding exon 24) of the LAMA1 gene. This alteration results from a C to T substitution at nucleotide position 3446, causing the proline (P) at amino acid position 1149 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |